Real-life use of ceftobiprole for severe infections in a French intensive care unit.

Ceftobiprole Critical illness Infectious disease Microbiology Pharmacokinetics

Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
27 Sep 2023
Historique:
received: 29 06 2023
revised: 19 09 2023
accepted: 21 09 2023
pubmed: 30 9 2023
medline: 30 9 2023
entrez: 29 9 2023
Statut: aheadofprint

Résumé

Ceftobiprole (CBP) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin with a wide spectrum of activity. We aimed to describe our experience of real-life use of CBP for the treatment of severe infections of critically ill patients with multiple infected sites and related trough CBP concentrations. We performed a retrospective, observational, monocentric study in our intensive care unit (ICU) that included all patients treated with CBP for documented infections between January 2016 and December 2021. We collected demographic, clinical, and microbiological data. When available, we report the CBP trough concentrations. The primary endpoint was clinical cure at the end of treatment. The secondary endpoints were in-hospital mortality and documentation of the carriage of multidrug-resistant (MDR) bacteria not present before CBP treatment. Between January 2016 and December 2021, 47 patients were treated in the ICU with CBP. The main indication for treatment was pneumonia (51%) and most patients presented with associated bacteremia (72%). All infections were polymicrobial. A clinical cure was achieved for nearly 80% of the patients. Only five patients presented new carriage of MDR bacteria. In-hospital mortality was 32%. Out of 21 strains of Enterobacterales for which the MIC was available, 33% were considered to be resistant to CBP according to the EUCAST 2023 clinical breakpoint. Trough CBP concentrations were reported for 16 patients. In our real-life experience, treatment of ICU patients with CBP for polymicrobial severe infections resulted in most cases in a clinical cure. Monitoring of trough concentrations is critical, especially in cases of high MIC.

Identifiants

pubmed: 37774796
pii: S2666-9919(23)00152-5
doi: 10.1016/j.idnow.2023.104790
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104790

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hugo Bellut (H)

Service de réanimation, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France. Electronic address: hbellut@ght78sud.fr.

Marine Arrayago (M)

Service de réanimation, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Marlène Amara (M)

Service de biologie, unité de microbiologie, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Ariane Roujansky (A)

Service de réanimation, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Maité Micaelo (M)

Service de biologie, unité de microbiologie, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Fabrice Bruneel (F)

Service de réanimation, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Jean-Pierre Bedos (JP)

Service de réanimation, Hôpital A. Mignot, CH Versailles, 177 Rue de Versailles, 78157 Le Chesnay, France.

Classifications MeSH